Management of Pain in Patients with Chronic Kidney Disease

Introduction to Ketorolac Risks

Patients with chronic kidney disease (CKD) are at increased risk of acute kidney injury from a single dose of ketorolac due to its primary excretion by the kidneys and the critical role of kidney function in its clearance, as noted by the Kidney International guidelines 1
CKD patients are more susceptible to the nephrotoxic effects of medications, according to the Kidney International guidelines 1, 2

The American College of Oncology recommends acetaminophen as a first-line option for pain management in CKD patients, if liver function is normal, with a strength of evidence based on clinical guidelines 3
Low-dose opioids with appropriate renal dosing adjustments are also recommended as first-line options for CKD patients requiring pain management, as per the Annals of Oncology guidelines 3
For moderate to severe pain, fentanyl or buprenorphine (transdermal or IV) are considered safer options in CKD stages 4-5, as recommended by the Annals of Oncology guidelines 3

If a clinical decision is made to administer a single dose of ketorolac in a CKD patient, the Kidney International guidelines recommend monitoring renal function before and 24-48 hours after administration, with a strength of evidence based on clinical studies 1, 4
Ensuring adequate hydration before and after administration is also recommended, as per the Praxis Medical Insights guidelines, although this is not the preferred source, the Kidney International guidelines also support this recommendation 4
Avoiding concurrent use of other nephrotoxic medications is advised, according to the Kidney International guidelines 1, 2

The KDIGO guidelines emphasize considering benefits versus potential harms in CKD patients, given their susceptibility to nephrotoxic effects of medications, with a strength of evidence based on clinical guidelines 1, 2
The Kidney International guidelines recommend avoiding a single dose of ketorolac in CKD patients due to the significant risk of worsening kidney function and the availability of safer alternatives, with a strength of evidence based on clinical studies 1, 2